China Universal Asset Management Co. Ltd. Has $9.82 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

China Universal Asset Management Co. Ltd. lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 25.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 149,796 shares of the company’s stock after buying an additional 30,414 shares during the quarter. AstraZeneca comprises approximately 0.9% of China Universal Asset Management Co. Ltd.’s investment portfolio, making the stock its 19th largest holding. China Universal Asset Management Co. Ltd.’s holdings in AstraZeneca were worth $9,815,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of AZN. AQR Capital Management LLC raised its position in shares of AstraZeneca by 112.4% during the second quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock worth $1,067,000 after purchasing an additional 7,241 shares during the period. Truist Financial Corp raised its holdings in AstraZeneca by 4.6% during the second quarter. Truist Financial Corp now owns 250,478 shares of the company’s stock worth $19,535,000 after buying an additional 11,074 shares during the last quarter. Dana Investment Advisors Inc. bought a new position in shares of AstraZeneca in the second quarter valued at $204,000. Sanctuary Advisors LLC acquired a new position in shares of AstraZeneca during the second quarter valued at about $12,546,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its position in shares of AstraZeneca by 122.4% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,728 shares of the company’s stock worth $135,000 after acquiring an additional 951 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $70.76 on Friday. The business has a 50-day simple moving average of $67.08 and a 200 day simple moving average of $73.92. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The stock has a market cap of $219.43 billion, a price-to-earnings ratio of 33.86, a PEG ratio of 1.17 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the firm posted $0.87 earnings per share. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. On average, research analysts forecast that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.